Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
     
.
. .
.
Home
Health Commentaries
InteliHealth Dental
Drug Resource Center
Ask the Expert
Interactive Tools

InteliHealth Policies
Site Map

   Advertisement
carepass Ad
carepass Ad .
Diseases & Conditions Healthy Lifestyle Your Health Look It Up
Health News Health News
.
Health News
333
Medications
In Trials, Ecstasy Drug Helps the Traumatized ; Veterans Seek Treatment That Combines Mdma with Psychotherapy
In Trials, Ecstasy Drug Helps the Traumatized ; Veterans Seek Treatment That Combines Mdma with Psychotherapy
bhsuper_2012_11_20_INHT_0000-10686-KEYWORD.Missing
(International Herald Tribune) -- Veterans are seeking treatment from a husband-and-wife team that combines psychotherapy with a dose of MDMA.
1463143
InteliHealth
2012-11-20
t
General Health News
2012-12-20
.

In Trials, Ecstasy Drug Helps the Traumatized ; Veterans Seek Treatment That Combines Mdma with Psychotherapy
November 20, 2012

(International Herald Tribune) -- Veterans are seeking treatment from a husband-and-wife team that combines psychotherapy with a dose of MDMA.

Hundreds of Iraq and Afghanistan veterans who suffer from post-traumatic stress have contacted a husband-and-wife team who work out of their home in suburban South Carolina to seek help. Many are desperate, pleading for treatment and willing to travel to get it.

The soldiers have no interest in traditional talking cures or prescription drugs that have given them little relief. They want to try an alternative: MDMA, better known as ecstasy, a drug that surfaced in the 1980s and '90s that can induce pulses of euphoria and a radiating affection. The government criminalized the drug in 1985, placing it on a list of prohibited substances that includes heroin and LSD. But regulators have licensed a small number of labs in recent years to produce MDMA for research purposes.

"I feel survivor's guilt, both for coming back from Iraq alive and now for having had a chance to do this therapy," said Anthony, a 25-year-old living near Charleston, South Carolina, who asked that his last name not be used because of the stigma of taking the drug. "I'm a different person because of it."

In a paper posted online Tuesday by the Journal of Psychopharmacology, Michael and Ann Mithoefer, the husband-and-wife team offering the treatment -- which combines psychotherapy with a dose of MDMA -- write that they found 15 of 21 people who recovered from severe post-traumatic stress in the therapy in the early 2000s reported minor to virtually no symptoms today.

The patients in this group included mostly rape victims, and experts familiar with the work cautioned that it was preliminary and its applicability to war trauma unknown. A Defense Department spokeswoman said the military was not involved in research of MDMA.

But given the scarcity of good treatment for post-traumatic stress, "there is a tremendous need to study novel medications" including MDMA, said John H. Krystal, chairman of psychiatry at the Yale School of Medicine.

The study is the first long-term test to suggest that psychiatrists' tentative interest in hallucinogens and other recreational drugs -- which have been taboo since the 1960s -- could pay off. And news that the Mithoefers are beginning to test the drug in veterans is out, in the military media and on veterans' blogs. "We've had more than 250 vets call us, there's a long waiting list, we wish we could enroll them all," Michael Mithoefer said.

The couple, working with other researchers, will treat no more than 24 veterans with the therapy, following Food and Drug Administration protocols for testing an experimental drug; MDMA is not approved for any medical uses.

A handful of similar experiments using MDMA, LSD or marijuana are now in the works in Britain, Israel, Switzerland and the United States. Military and civilian researchers alike are watching closely. So far, the research has been largely supported by nonprofit groups.

Two people who have had the therapy -- Anthony, in the veterans study, and another who received the therapy independently -- said in interviews that MDMA produced a mental sweet spot that allowed them to feel and talk about their trauma without being overwhelmed by it.

"It changed my perspective on the entire experience of working at ground zero," said Patrick, a 46-year-old living in San Francisco, who worked long hours in the rubble after the attacks of Sept. 11, 2001, searching in vain for survivors, as desperate family members of the victims pleaded for information. "At times I had this beautiful, peaceful feeling down in the pit, that I had a purpose, that I was doing what I needed to be doing. And I began in therapy to identify with that," rather than the guilt and sadness.

The Mithoefers administer the MDMA in two doses over one long therapy session, which comes after a series of weekly nondrug sessions to prepare. Three to five weeks later, they perform another drug-assisted session; and again, patients engage in 90-minute nondrug therapy before and after, once each week. Most have found that their score on a standard measure of symptoms -- general anxiety, hyperarousal, depression, nightmares -- drops by about 75 percent. That is more than twice the relief experienced by people who get psychotherapy without MDMA.

The couple works as a team, sitting with the patient for as long as the altered state lasts. "It's very much a nondirected therapy," Dr. Mithoefer said, adding: "We're with them for 8 to 10 hours, usually, and we alternate between having them talk to us, and having them focus on the trauma. Part of what we're trying to do is help the person stay with the memory even if it's difficult."

For many people, the treatment is very vivid emotionally, Dr. Mithoefer continued. The drug does not produce a "high," but it usually brings some tranquillity. Studies of people taking MDMA suggest that the drug induces, among other things, the release of a hormone called oxytocin, which is thought to increase sensations of trust and affection. The drug also seems to tamp down activity in the amygdala region of the brain, which flares during fearful, threatening situations.

"The feeling I got was nothing at all for 45 minutes, then really bad anxiety, and I was fighting it at first," said Anthony, the Iraq veteran, who patrolled southwest of Baghdad in 2006 and 2007 amid relentless insurgent harassment and bombings. "And then -- I don't know how to put it, exactly -- I felt O.K. and messed up at the same time. Clear. It was almost like I could go into any thought I wanted and fix it."

For instance, he could think and talk about an attack that occurred in a town near Baghdad, in which Iraqis posing as allies -- and who had been armed by the U.S. military -- turned their guns on American troops, killing several. The unit could not quickly evacuate its wounded because of weather conditions. Anthony's rage and grief were so overwhelming that he had to suppress them and did so for years. "The military does a great job of turning you into a soldier, of teaching you how to control your reactions," Anthony said, and it is hard to turn those habits off.

He said he no longer struggled with post-traumatic anxiety or guilt, more than a year after undergoing the MDMA-assisted treatment.

In the report, the Mithoefers write that they found 80 percent of the patients treated in the early 2000s reported that most or all of the initial benefit they achieved persisted for a year to five years after the therapy ended. If the veterans' results are anywhere near as powerful and lasting, researchers said, it is likely that the U.S. government would be willing to finance a much larger trial.

"That is really what we're aiming for, and we're doing it carefully," said Rick Doblin, the executive director of the Multidisciplinary Association for Psychedelic Studies, which financed the MDMA study. "After all this cultural turmoil, the split between the military and the psychedelic community, it would really be something if we could come together and use some of these drugs to help people."

(C) 2012 International Herald Tribune. via ProQuest Information and Learning Company; All Rights Reserved

.
InteliHealth
. . . .
.
More News
InteliHealth .
.
General Health
Top News
This Week In Health
Addiction
Allergy
Alzheimer's
Asthma
Arthritis
Babies
Breast Cancer
Cancer
Caregiving
Cervical Cancer
Children's Health
Cholesterol
Complementary & Alternative Medicine
Dental / Oral Health
Depression
Diabetes
Ear, Nose And Throat
Environmental Health
Eyes
Family Health
Fitness
Genetics
Headache
Health Policy
HIV / AIDS
Heart Health
Lung Cancer
Medications
Infectious Diseases
Men's Health
Nutrition News
Mental Health
Multiple Sclerosis
Nutrition Guide
Parkinson's
Pregnancy
Prevention
Prostate Cancer
Senior Health
Sexual / Reproductive Health
Sleep
Tobacco Cessation
STDs
Stress Reduction
Stroke
Weight Management
Today In Health History
Women's Health
Workplace Health
.
.
.
.
InteliHealth

   
21291
.
.  
This website is certified by Health On the Net Foundation. Click to verify.
.
Chrome 2001
Chrome 2001